First Targeted Therapy for Pancreatic Cancer Approved | Tampa News

Pancreatic cancer just got a major breakthrough: FDA approves Rasonque, the first targeted therapy to attack the mutated KRAS protein driving 80-90% of cases. In a trial of 500 metastatic patients, it boosted median survival from 6.7 to over 13 months—offering hope for surgery as a potential cure. Side effects include rash, diarrhea, nausea, and fatigue, but this daily pill could redefine treatment for advanced disease. Listen in comfort:Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/e887020c54ce423b